What is the current status of S 1095?

S 1095 is currently: Introduced.

Who sponsored S 1095?

S 1095 was sponsored by Amy Klobuchar (D), Sen.

IntroducedN/A

Introduced1 year ago

Intro

Senate

House

Pres

Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Why This Matters

This bill allows the Federal Trade Commission to combat false petitions that delay the approval of generic drugs and biosimilars.

If you rely on generic drugs, this bill helps ensure they are approved faster by stopping false delays.

Who this affects

pharmaceutical companies · consumers

What changes is this bill making?

1This bill allows the Federal Trade Commission to take action against false petitions that delay drug approvals.
2It defines a 'sham' petition as one that is baseless and intended to interfere with a competitor's business.
3The bill enables civil actions against those who submit these false petitions, seeking penalties and other relief.
4If the Secretary of Health and Human Services identifies a petition as intended to delay approval, it can be presumed sham.
5This legislation aims to promote competition and ensure that legitimate health concerns are addressed efficiently.